Literature DB >> 12566335

Current concepts in the diagnosis and management of Parkinson's disease.

Mark Guttman1, Stephen J Kish, Yoshiaki Furukawa.   

Abstract

Parkinson's disease is a progressive neurological disorder characterized by rest tremor, bradykinesia, rigidity and postural instability. The cause is unknown, but growing evidence suggests that it may be due to a combination of environmental and genetic factors. Treatment during the early stage of Parkinson's disease has evolved, and evidence suggests that dopamine agonist monotherapy may prevent the response fluctuations that are associated with disease progression. L-dopa therapy, however, remains the most efficacious treatment. Treatment during the advanced stage focuses on improving control of a number of specific clinical problems. Successful management of motor response fluctuations (e.g., "wearing off," on-off fluctuations, nighttime deterioration, early morning deterioration and dyskinesias) and of psychiatric problems is often possible with specific treatment strategies. Surgical treatment is an option for a defined patient population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566335      PMCID: PMC140472     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  31 in total

Review 1.  Etiology of Parkinson's disease.

Authors:  A J Stoessl
Journal:  Can J Neurol Sci       Date:  1999-08       Impact factor: 2.104

2.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 3.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease.

Authors:  T Brücke; S Djamshidian; G Bencsits; W Pirker; S Asenbaum; I Podreka
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

Review 4.  Genetics of Parkinson's disease.

Authors:  T Gasser
Journal:  J Neurol       Date:  2001-10       Impact factor: 4.849

5.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

Authors:  C M van Duijn; M C Dekker; V Bonifati; R J Galjaard; J J Houwing-Duistermaat; P J Snijders; L Testers; G J Breedveld; M Horstink; L A Sandkuijl; J C van Swieten; B A Oostra; P Heutink
Journal:  Am J Hum Genet       Date:  2001-07-02       Impact factor: 11.025

6.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

Authors:  J A Obeso; C W Olanow; M C Rodriguez-Oroz; P Krack; R Kumar; A E Lang
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

7.  Genome-wide scan for Parkinson's disease: the GenePD Study.

Authors:  A L DeStefano; L I Golbe; M H Mark; A M Lazzarini; N E Maher; M Saint-Hilaire; R G Feldman; M Guttman; R L Watts; O Suchowersky; A L Lafontaine; N Labelle; M F Lew; C H Waters; J H Growdon; C Singer; L J Currie; G F Wooten; P Vieregge; P P Pramstaller; C Klein; J P Hubble; M Stacy; E Montgomery; M E MacDonald; J F Gusella; R H Myers
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

8.  Familial aggregation of Parkinson's disease in Iceland.

Authors:  S Sveinbjörnsdottir; A A Hicks; T Jonsson; H Pétursson; G Guğmundsson; M L Frigge; A Kong; J R Gulcher; K Stefansson
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

Review 9.  Functional imaging in Parkinson's disease.

Authors:  A Dagher
Journal:  Semin Neurol       Date:  2001       Impact factor: 3.420

10.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

View more
  25 in total

1.  ECT for Parkinson's?

Authors:  B A Martin
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

2.  Practice recommendations for Parkinson's disease: Assessment and management by community pharmacists.

Authors:  Tejal Patel; Feng Chang
Journal:  Can Pharm J (Ott)       Date:  2015-05

Review 3.  Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors:  Andrew Lees
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  A novel device for continuous monitoring of tremor and other motor symptoms.

Authors:  Luigi Battista; Antonietta Romaniello
Journal:  Neurol Sci       Date:  2018-05-07       Impact factor: 3.307

Review 5.  Recognition and management of neuropsychiatric complications in Parkinson's disease.

Authors:  Florian Ferreri; Catherine Agbokou; Serge Gauthier
Journal:  CMAJ       Date:  2006-12-05       Impact factor: 8.262

6.  Quality of life related to swallowing in Parkinson's disease.

Authors:  Danielle Carneiro; Maria das Graças Wanderley de Sales Coriolano; Luciana Rodrigues Belo; Aneide Rocha de Marcos Rabelo; Amdore Guescel Asano; Otávio Gomes Lins
Journal:  Dysphagia       Date:  2014-06-22       Impact factor: 3.438

7.  Parkinson's disease guidelines for pharmacists.

Authors:  Tejal Patel; Feng Chang
Journal:  Can Pharm J (Ott)       Date:  2014-05

8.  Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis.

Authors:  Shiek S S J Ahmed; Winkins Santosh
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

9.  Deep brain stimulation for Parkinson's disease and other movement disorders: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

10.  Medical decision making for patients with Parkinson disease under Average Cost Criterion.

Authors:  John E Goulionis; Athanassios Vozikis
Journal:  Aust New Zealand Health Policy       Date:  2009-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.